Conclusion of an agreement with the European Innovation Council and SMEs Executive Agency (EISMEA) for the implementation and co-financing of project CT-03

Current report no. 51/2025

Drafting date: 24 October 2025

Subject: Conclusion of an agreement with the European Innovation Council and SMEs Executive Agency (EISMEA) for the implementation and co-financing of project CT-03.

Legal basis: Article 17(1) MAR - confidential information.

The Management Board of Captor Therapeutics S.A. with its registered office in Wrocław (the ‘Company’), with reference to report No. 12/2025 of 17 February 2025, in which the Company announced that its project had been selected for funding in the EIC Accelerator competition under the Horizon Europe programme, project CT-03: ‘A First-in-Class MCL-1 degrader to promote apoptosis in therapy-resistant liquid and solid tumours’, hereby announces that on 24 October 2025 an agreement was signed between the Company and the European Innovation Council and SMEs Executive Agency (EISMEA) for the implementation and co-financing of the above-mentioned Project.

The project aims to demonstrate safety and lack of cardiotoxicity in humans in a Phase Ia/Ib clinical trial in patients with acute myeloid leukaemia (AML).

The requested total funding for the project is €7.8 million. The funding includes €2.5 million in grant financing and a possible equity investment of European Investment Bank in the amount of €5.3 million.